Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 1/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13361289 | 0.87 | RAMP1 (0.48) | RAMP1CALCRLOPRD1ADRB2EPHX2 | |
| SCHEMBL4720819 | 0.85 | RAMP1 (0.50) | RAMP1CALCRLOPRD1ADRB2DPP4 | |
| SCHEMBL5248991 | 0.84 | RAMP1 (0.59) | RAMP1CALCRLOPRD1ADRB2EPHX2 | |
| SCHEMBL4718770 | 0.84 | RAMP1 (0.49) | RAMP1CALCRLADRB2DPP4FAP | |
| SCHEMBL4720730 | 0.84 | RAMP1 (0.49) | RAMP1CALCRLADRB2DPP4FAP | |
| Hydrochloric Acid SCHEMBL3306020 | 0.83 | RAMP1 (0.49) | RAMP1CALCRLADRB2DPP4FAP | |
| SCHEMBL4763045 | 0.77 | AKT1 (0.47) | DPP4DPP8DPP7 | |
| SCHEMBL3309849 | 0.75 | GRB2 (0.44) | ADRB2 | |
| SCHEMBL3309854 | 0.75 | GRB2 (0.44) | ADRB2 | |
| SCHEMBL3314750 | 0.75 | RAMP1 (0.59) | RAMP1CALCRLADRB2EPHX2L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | claimed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | RAMP1 84/4885CALCRL 1/4885OPRD1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.